Robert L. Ferris

1995–2026 年に発表

262
論文数
47,254
被引用数
113
h 指数
251
i10 指数

被引用数

Robert L. Ferris の年別被引用数1995 年: 被引用 2 件1996 年: 被引用 1 件1997 年: 被引用 3 件1998 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 6 件2001 年: 被引用 4 件2002 年: 被引用 2 件2003 年: 被引用 6 件2004 年: 被引用 7 件2005 年: 被引用 38 件2006 年: 被引用 58 件2007 年: 被引用 66 件2008 年: 被引用 78 件2009 年: 被引用 69 件2010 年: 被引用 102 件2011 年: 被引用 100 件2012 年: 被引用 110 件2013 年: 被引用 194 件2014 年: 被引用 195 件2015 年: 被引用 307 件2016 年: 被引用 346 件2017 年: 被引用 582 件2018 年: 被引用 549 件2019 年: 被引用 1,991 件2020 年: 被引用 2,440 件2021 年: 被引用 2,549 件2022 年: 被引用 2,078 件2023 年: 被引用 1,655 件2024 年: 被引用 2,453 件2025 年: 被引用 1,247 件2026 年: 被引用 35 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,227 件、この内訳の 26.8%中国: 引用元論文 3,174 件、この内訳の 16.3%イタリア: 引用元論文 965 件、この内訳の 4.9%ドイツ: 引用元論文 908 件、この内訳の 4.7%イギリス: 引用元論文 824 件、この内訳の 4.2%フランス: 引用元論文 673 件、この内訳の 3.5%日本: 引用元論文 669 件、この内訳の 3.4%カナダ: 引用元論文 616 件、この内訳の 3.2%スペイン: 引用元論文 488 件、この内訳の 2.5%オランダ: 引用元論文 456 件、この内訳の 2.3%オーストラリア: 引用元論文 440 件、この内訳の 2.3%韓国: 引用元論文 439 件、この内訳の 2.3%
0%26.8%その他 23.6%

分野

  • Medicine62.8%
  • Biochemistry, Genetics and Molecular Biology20.1%
  • Immunology and Microbiology13%
  • Engineering0.9%
  • Neuroscience0.6%
  • Dentistry0.5%
  • その他2.1%

トピック

  • Cancer Immunotherapy and Biomarkers9.8%
  • Head and Neck Cancer Studies6.2%
  • Immunotherapy and Immune Responses4.4%
  • Immune Cell Function and Interaction4.4%
  • Thyroid Cancer Diagnosis and Treatment3.4%
  • CAR-T cell therapy research2.9%
  • その他68.9%

共著者

全論文

検索で開く
  1. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    著者: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 5,078

  2. Integrated Genomic Characterization of Papillary Thyroid Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Timothy A. Chan, Amy Y. Chen, Andrew D. Cherniack, Dorothy Cheung, Lynda Chin, Juok Cho, Andy Chu, Eric Chuah, Kristian Cibulskis, Giovanni Ciriello, Amanda Clarke, Gary L. Clayman, Leslie Cope, John A. Copland, Kyle R. Covington, Ludmila Danilova, Tanja M. Davidsen, John A. Demchok, Daniel DiCara, Noreen Dhalla, Rajiv Dhir, Sheliann S. Dookran, Gideon Dresdner, Jonathan Eldridge, Greg Eley, Adel K. El‐Naggar, Stephanie Eng, James A. Fagin, Timothy R. Fennell, Robert L. Ferris, Sheila Fisher, Scott Frazer, Jessica Frick, Stacey Gabriel, Ian Ganly, Jianjiong Gao, Levi A. Garraway, Julie M. Gastier-Foster, Gad Getz, Nils Gehlenborg, Ronald Ghossein, Richard A. Gibbs, Thomas J. Giordano, Karen Gomez-Hernandez, Jonna Grimsby, Benjamin Groß, Ranabir Guin, Angela Hadjipanayis, Hollie A. Harper, D. Neil Hayes, David I. Heiman, James G. Herman, Katherine A. Hoadley, Matan Hofree, Robert A. Holt, Alan P. Hoyle, Franklin W. Huang, Mei Huang, Carolyn M. Hutter, Trey Ideker, Lisa Iype, Anders Jacobsen, Stuart R. Jefferys, Corbin D. Jones, Steven J.M. Jones, Katayoon Kasaian, Electron Kebebew, Fadlo R. Khuri, Jaegil Kim, Roger Kramer ほか 143 名 - Cell 2014 被引用: 3,126

  3. Head and neck cancer

    著者: , , , - The Lancet 2008 被引用: 2,220

  4. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer

    著者: , , , , , , , , , , , , , , , - Immunity 2020 被引用: 679

  5. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 617

  6. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

    著者: , , , , , , , - Immunity 2016 被引用: 801

  7. Lipid accumulation and dendritic cell dysfunction in cancer

    著者: , , , , , , , , , , , , , , , , , , - Nature Medicine 2010 被引用: 699

  8. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma

    著者: , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 被引用: 358

  9. The changing therapeutic landscape of head and neck cancer

    著者: , , , - Nature Reviews Clinical Oncology 2019 被引用: 812

  10. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

    著者: , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2019 被引用: 738

  11. Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity

    著者: , , , , , , , , , , , , , , , , , - Cell 2017 被引用: 624

  12. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 被引用: 293

  13. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment

    著者: , , , , , - Nature reviews. Cancer 2022 被引用: 290

  14. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 被引用: 280

  15. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 441

  16. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

    著者: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 365

  17. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

    著者: , , , , , , , , , , , , , , , , , , , , - Oral Oncology 2018 被引用: 800

  18. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

    著者: , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2021 被引用: 222

  19. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 158

  20. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 被引用: 141

  21. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

    著者: , , , , , - OncoImmunology 2016 被引用: 301

  22. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Linwah Yip, Yuri E. Nikiforov - JAMA Oncology 2018 被引用: 464

  23. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment

    著者: , , , , , , , , , , , - Cell Reports 2021 被引用: 93

  24. Immunology and Immunotherapy of Head and Neck Cancer

    著者: - Journal of Clinical Oncology 2015 被引用: 668